INTRODUCTION INTO PPPM: EXPERIENCE OF THE PAST AND TOMORROW’S REALITY

Cover Page


Cite item

Full Text

Abstract

Health service today is on the verge of broad changes. The intensive practical application of the achievements of genomics, proteomics, metabolomics and bioinformatics has significantly deepened and continues to deepen our view of the pathological processes taking place at a level of biostructures. In the nearest future this progress will give medical practitioners the opportunity to focus on a subclinical stage of the disease, i.e. on the earliest stages of the pathological process. This will require the prediction of disease development risks, subclinical diagnostics with the precise staging of the pathological process, and, finally, the application as early as possible of targeted pharmacotherapeutic methods in order to prevent the manifestation of the disease or its progression into more severe stages. All these principles create the framework of a fundamentally new «3P» strategy in medicine: predictive, preventive and personalized medicine.

 

About the authors

T. A. Bodrova

National Research University «Higher School of Economics», Moscow, Russian Federation
University of World Politics and Law, The Diplomatic Academy of the Ministry of Foreign Affairs of Russian Federation, Moscow, Russian Federation

Author for correspondence.
Email: tatianabodrova@gmail.com

Master of Science, Researcher of National Research University «Higher School of Economics» Address: 101000, Moscow, Myasnitskaya St., 20, tel.: (495) 771-32-32, fax: (495) 628-79-31

Россия

D. S. Kostushev

A.I. Evdokimov Moscow State Medical Stomatological University Moscow, Russian Federation

Email: dkostushev@gmail.com

Intern Researcher of Department of Pathology I.M. Sechenov First Moscow State Medical University. Address: 119991, Moscow, Trubetskaya St., 8/2

Россия

E. N. Antonova

A.I. Evdokimov Moscow State Medical Stomatological University Moscow, Russian Federation

Email: dkostushev@gmail.com
Intern Researcher of Department of Pathology I.M. Sechenov First Moscow State Medical University. Address: 119991, Moscow, Trubetskaya St., 8/2; tel.: (495) 609-67-00 Россия

D. A. Gnatenko

A.I. Evdokimov Moscow State Medical Stomatological University Moscow, Russian Federation

Email: gnatenkodmitrij@gmail.com

Intern Researcher of Department of Pathology I.M. Sechenov First Moscow State Medical University.Address: 119991, Moscow, Trubetskaya St., 8/2

Россия

M. O. Bocharova

A.I. Evdokimov Moscow State Medical Stomatological University Moscow, Russian Federation

Email: maria.bocciarova@gmail.com

Intern Researcher of Department of Pathology I.M. Sechenov First Moscow State Medical University. Address: 119991, Moscow, Trubetskaya St., 8/2

Россия

Yu. M. Lopukhin

Scientific-Research Institute of Physical Chemical Medicine Moscow, Russian Federation

Email: yuri.lopukhin@ripcm.org.ru
PhD, Academician of the Russian Academy of Medical Science, Honorary Director of Scientific Research Institute of Physical-Chemical Medicine
Address: Moscow, Malaya Pirogovskaya 1a; tel.: (499) 246-45-16 Россия

M. A. Pal'tsev

National Research Centre «Kurchatov Institute», Moscow, Russian Federation

Email: tatianabodrova@gmail.com

PhD, the Academician of the Russian Academy of Medical Sciences, Deputy Director for Medical-Biological Research, Research Center «Kurchatov Institute» Address: 123182, Moscow, Academician Kurchatov Square, 1; tel.: (499) 196-95-39 

Россия

S. V. Suchkov

I.M. Sechenov First Moscow State Medical University, Russian Federation

Email: ssuchkov57@gmail.com
PhD, Professor of Department of Pathology I.M. Sechenov First Moscow State Medical University, Professor of Department of A.I. Evdokimov Clinical Immunology,
Address: 119991, Moscow, Trubetskaya St., 8/2; tel.: (495) 708-31-56 Россия

References

  1. Ray R. The future of medicine. Am. J. Med. 2012; 125 (3): 236–239.
  2. Jones T, Price P. Development and experimental medicine applications of PET in oncology: a historical perspective. Lancet Oncol. 2012 Mar;13(3); 116–125.
  3. Patel N.R., McPhail M.J., Shariff M.I., Keun H.C., Taylor-Robinson S.D. Biofluid metabonomics using (1)H NMR spectroscopy: the road to biomarker discovery in gastroenterology and hepatology. Exp. Rev. Gastroenterol. Hepatol. 2012 Apr;6(2); 239–251.
  4. Henderson J. Health economics and Policy. Cincinnati, Ohio: South-Western College publishing. 1999. P. 1–30, 290–321, 378–414.
  5. Hood L., Balling R., Auffray C. Revolutionizing medicine in the 21(st) century through systems approaches. Biotechnol. J. 2012; 002/biot.201100306
  6. Tran B., Dancey J.E., Kamel-Reid S., McPherson J.D., Bedard P.L., Brown A.M., Zhang T., Shaw P., Onetto N., Stein L., Hudson T.J., Neel B.G., Siu L.L. Cancer genomics: technology, discovery, and translation. J. Clin. Oncol. 2012; 30 (6): 647–660.
  7. Hagmann H., Thadhani R., Benzing T., Karumanchi S.A., Stepan H. The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin. Chem. 2012; 58 (5): 837–845.
  8. Moons K.G., Kengne A.P., Woodward M., Royston P., Vergouwe Y., Altman D.G., Grobbee D.E. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart. 2012; 98 (9): 683–690.
  9. Moons K.G., Kengne A.P., Grobbee D.E., Royston P., Vergouwe Y., Altman D.G., Woodward M. Risk prediction models: II. External validation, model updating, and impact assessment. Heart. 2012; 98 (9): 691–698.
  10. Saubermann A.J., Lagasse R.S. Prediction of rate and severity of adverse perioperative outcomes: «normal accidents» revisited. Mt. Sinai J. Med. 2012; 79 (1): 46–55. doi: 10.1002/msj.21295.
  11. Farra N., Manickaraj A.K., Ellis J., Mital S. Personalized medicine in the genomics era: highlights from an international symposium on childhood heart disease. Future Cardiol. 2012; 8 (2): 157–160.
  12. Suchkov S.V., Martynov L.A,, Vinokurov I.A., Kostyushe D.S., Andreeva A.A., Gadzhieva S.I., Gnatenko D.A., Shonfild I., Lopukhin Yu.M., Notkins A., Pal'tsev M.A. On the prospects of preclinical diagnosis within the objectives of preventive and preventive and predictive medicine. Efferentnaya i fiziko-khimicheskaya meditsina – Efferent and physico-chemical medicine. 2010; 63–74.
  13. Maeng J.H., Lee B.C., Ko Y.J., Cho W., Ahn Y., Cho N.G., Lee S.H., Hwang S.Y. A novel microfluidic biosensor based on an electrical detection system for alpha-fetoprotein. Biosens Bioelectron. 2008; 23 (9): 1319–1325. Epub 2007 Dec 5.
  14. Stewart S.E., Yu D., Scharf J.M., Neale B.M., Fagerness J.A., Mathews C.A., Arnold P.D., Evans P.D., Gamazon E.R., Osiecki L., McGrath L., Haddad S., Crane J., Hezel D., Illman C., Mayerfeld C., Konkashbaev A., Liu C., Pluzhnikov A., Tikhomirov A., Edlund C.K., Rauch S.L., Moessner R., Falkai P., Maier W., Ruhrmann S., Grabe H.J., Lennertz L., Wagner M., Bellodi L., Cavallini M.C., Richter M.A., Cook E.H. Jr., Kennedy J.L., Rosenberg D., Stein D.J., Hemmings S.M., Lochner C., Azzam A., Chavira D.A., Fournier E., Garrido H., Sheppard B., Umaña P., Murphy D.L., Wendland J.R., Veenstra-Vanderweele J., Denys D., Blom R., Deforce D., Van Nieuwerburgh F., Westenberg H.G., Walitza S., Egberts K., Renner T., Miguel E.C., Cappi C., Hounie A.G., Conceição do Rosário M., Sampaio A.S., Vallada H., Nicolini H., Lanzagorta N., Camarena B., Delorme R., Leboyer M., Pato C.N., Pato M.T., Voyiaziakis E., Heutink P., Cath D.C., Posthuma D., Smit J.H., Samuels J., Bienvenu O.J., Cullen B., Fyer A.J., Grados M.A., Greenberg B.D., McCracken J.T., Riddle M.A., Wang Y., Coric V., Leckman J.F., Bloch M., Pittenger C., Eapen V., Black D.W., Ophoff R.A., Strengman E., Cusi D., Turiel M., Frau F., Macciardi F., Gibbs J.R., Cookson M.R., Singleton A., Hardy J., Crenshaw A.T., Parkin M.A., Mirel D.B., Conti D.V., Purcell S., Nestadt G., Hanna G.L., Jenike M.A., Knowles J.A., Cox N., Pauls D.L. Genome-wide association study of obsessive-compulsive disorder. Mol. Psychiatry. 2012; doi: 10.1038/mp.2012.85.
  15. Pal'tsev M.A., Cherepakhina N.E., Shoenfeld Y., Shogenov Z.S., Tabaksoeva Zh.A., Agirov M.M., Suchkov S.V. Post-infection clinico-immunologic syndrome: fundamentals of etiopathogenesis and immunogenodiagnostic strategy Vestn. Ross. Akad. Med. Nauk – Annals of Academy of Medical Sciences. 2009; 10: 25–31.
  16. Suchkov S., Kostyushev D., Gnatenko D., Gadzhieva S. and Paltsev M. Preclinical and predictive algorithms in monitoring patients with autoimmune diseases and their relatives-at-risk. Autoimmune disorders ― current concepts and advances from bedside to mmechanistic insights. Fang-Ping Huang (ed.). 2011. ISBN: 978-953-307-653-9, InTech
  17. Kostyushev D., Tsarev I., Gnatenko D., Paltsev M., Suchkov S. Myelin-associated serological targets as applicable to diagnostic tools to be used at the preclinical and transient stages of multiple sclerosis progression. Open J. Immunol. 2011; 1 (3): 80–86. doi: 10.4236/oji.2011.13010 Copyright
  18. Kelloff G.J., Sigman C.C. Cancer biomarkers: selecting the right drug for the right patient. Nat. Rev. Drug Discov. 2012; 11 (3): 201–214.
  19. Robinton D.A., Daley G.Q. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012; 481 (7381): 295–305.
  20. Sheiman I., Shishkin S. New challenges and new objectives problems of economic transition. Russian Health Care. 2010; 52 (12): 4–49.
  21. Pozgar, George D. Legal aspects of health care administration. 10th ed. NY, 2007. Chapter 21.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 1970 "Paediatrician" Publishers LLC



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies